AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$OFIX

Fisher Patrick sold $13K of OFIX

Fisher Patrick (President, Global Limb Recon) sold 1,295 shares of Orthofix Medical Inc. (OFIX) at $10.09 on 2026-08-18.

Original reporting
SEC EDGAR · Fisher Patrick
Published Aug 20, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OFIX
Neutral
high confidence
Mentioned
$OFIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXNeutralLow
01

Why it matters

The sale is modest and does not indicate a change in company fundamentals.

02

Market read

Routine insider sell with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or clinical trial news could change the relevance of this insider activity.

Relevance 3/10Novelty 4/10Timing: filed after market on 2026-08-20

Background

Form 4 filings disclose insider trades; investors monitor them for signals of confidence.

Company-level read

Ticker impact

$OFIXNeutralHigh confidence
Context

President Fisher Patrick sold 1,295 shares for $13,066, reducing his stake to 51,219 shares.

Expected impact

No significant price change expected.

Evidence & confidence

The transaction size is small relative to float and market cap; typical routine sale.

Market effects

Sector

None; Orthofix operates in medical devices with no sector-wide impact from this sale.

Regional

No regional effect; the filing is a routine US insider transaction.

Global

Minimal; limited to investors tracking insider activity.

Counterpoint

What could challenge this read

If the insider is signaling concerns, a short position could be considered, but evidence is weak.

Key entities

  • Company
    Orthofix Medical Inc.

    Medical device manufacturer listed on NASDAQ (OFIX).

  • Executive
    Fisher Patrick

    President, Global Limb Recon at Orthofix.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OFIX insider trading history →

Related articles

AUG 5
$OFIXMed

Orthofix Medical Inc. Q2 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q2 2026 earnings call updates, emphasizing a shift toward distributor quality and asset utilization. Management expects 2026 net sales and EBITDA guidance to rise by $7 million, citing $12 million Medicare reimbursement restoration and $15 million European distributor benefit, partly offset by weaker smaller spine distributors. Medicare bone stimulator reimbursement was restored retroactive to May 18, 2026.

yahoo.com7 min
JUL 21
$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

benzinga.com7 min
JUL 7
$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

rttnews.com6 min
JUL 6
$OFIXMedAI 8/10

Why is Orthofix Medical stock surging today? By Investing.com

Orthofix Medical shares rose 15.3% after the company said CMS reversed earlier Medicare billing/fee-schedule changes for non-invasive bone growth stimulators, restoring reimbursement to prior levels. CMS issued revised guidance July 1, 2026, withdrawing modifications tied to HCPCS codes. The stock moved from near $8.85 toward $11.46; insiders sold about $2.7M over three months.

investing.com4 min